Raphael Augusto Correa Bastianon Santiago, MD in Aurora, CO - Medicare Student in an Organized Health Care Education/Training Program

Raphael Augusto Correa Bastianon Santiago, MD is a medicare enrolled "Student In An Organized Health Care Education/training Program" physician in Aurora, Colorado. His current practice location is 13123 E 16th Ave, Aurora, Colorado. You can reach out to his office (for appointments etc.) via phone at (954) 505-9409.

Raphael Augusto Correa Bastianon Santiago is licensed to practice in Colorado (license number TL.0009866) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1922794403.

Contact Information

	Raphael Augusto Correa Bastianon Santiago, MD
	13123 E 16th Ave, Aurora, CO 80045-7106
	(954) 505-9409
	Not Available

Physician's Profile

Full Name	Raphael Augusto Correa Bastianon Santiago
Gender	Male
Speciality	Student In An Organized Health Care Education/training Program
Location	13123 E 16th Ave, Aurora, Colorado
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1922794403
Provider Enumeration Date: 04/17/2023
Last Update Date: 06/30/2023

Medicare PECOS Information:

PECOS PAC ID: 9830559053
Enrollment ID: I20230720000509

Medical Identifiers

Medical identifiers for Raphael Augusto Correa Bastianon Santiago such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1922794403	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207T00000X	Neurological Surgery	34231HSE (Florida)	Secondary
390200000X	Student In An Organized Health Care Education/training Program	TL.0009866 (Colorado)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Raphael Augusto Correa Bastianon Santiago is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Raphael Augusto Correa Bastianon Santiago, MD 2950 Cleveland Clinic Blvd, Weston, FL 33331-3625 Ph: () -	Raphael Augusto Correa Bastianon Santiago, MD 13123 E 16th Ave, Aurora, CO 80045-7106 Ph: (954) 505-9409

News Archive

Wearable device may more accurately assess the effects of hemorrhage blood loss

Emergency medical technicians (EMTs), military medics, and emergency room physicians could one day be better able to treat victims of vehicular accidents, gunshot wounds, and battlefield injuries thanks to a new device under development that may more accurately assess the effects of blood loss due to hemorrhage.

ETView's VivaSight-DL product family receives pre-market clearance

ETView today announced that the company has received pre-market clearance for the VivaSight-DL product family following review of a Technical File submission by Medical Device Certification.

Scientists create leaner and meaner E. coli

By stripping the E. coli genome of vast tracts of its genetic material - hundreds of apparently inconsequential genes - a team of Wisconsin researchers has created a leaner and meaner version of the bacterium that is a workhorse of modern biology and industry.

Hearing loss is linked to income loss

Sonic Innovations (http://sonici.com), a U.S.-based digital hearing aid manufacturer, warns Americans who ignore a hearing loss are also losing income. A study from the Better Hearing Institute (BHI) (http://betterhearing.org), a non-profit corporation that educates the public about the neglected problem of hearing loss and what can be done about it, gives the numbers.

Experimental vaccine induces neutralizing antibodies against SARS-CoV-2

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New England Journal of Medicine.

Raphael Augusto Correa Bastianon Santiago, MD - Medicare Student in an Organized Health Care Education/Training Program in Aurora, CO